Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Multiple Myeloma 16Leukemia, Myeloid, Acute 16Myelodysplastic Syndromes 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 9Leukemia 8Burkitt Lymphoma 8Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 6Hodgkin Disease 6Congenital Abnormalities 6Sarcoma 5Recurrence 5Neoplasms, Plasma Cell 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Central Nervous System Neoplasms 4Breast Neoplasms 4Wilms Tumor 3Retinoblastoma 3Neuroblastoma 3Neoplasm Metastasis 3Myeloproliferative Disorders 3Medulloblastoma 3Lymphoma, Large-Cell, Immunoblastic 3Leukemia, Myelomonocytic, Juvenile 3

Interventions

Filgrastim 3Carboplatin 3sodium thiosulfate 2etoposide phosphate 2Radiotherapy 2Cyclophosphamide 2Amifostine 2pegfilgrastim 1glucarpidase 1Triptorelin Pamoate 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Paclitaxel 1Melphalan 1Mannitol 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Cytarabine 1Cisplatin 1Celecoxib 1Capecitabine 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Drug-Related Side Effects and Adverse Reactions × Granulocyte Colony-Stimulating Factor × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡